Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 1;159(10):1068-1075.
doi: 10.1001/jamadermatol.2023.2822.

Overall Survival After Mohs Surgery for Early-Stage Merkel Cell Carcinoma

Shayan Cheraghlou  1 , Nicole A Doudican  1 , Maressa C Criscito  1 , Mary L Stevenson  1 , John A Carucci  1
Affiliations

Overall Survival After Mohs Surgery for Early-Stage Merkel Cell Carcinoma

Shayan Cheraghlou et al. JAMA Dermatol. .

Abstract

Importance: Merkel cell carcinoma (MCC) is a rare cutaneous malignant neoplasm with increasing incidence and high mortality. Although it is accepted that the optimal treatment for localized tumors is surgical, the data surrounding the optimal surgical approach are mixed, and current National Comprehensive Cancer Network guidelines state that Mohs micrographic surgery (MMS) and wide local excision (WLE) can both be used. The current National Comprehensive Cancer Network guidelines do not advocate a preference for MMS or WLE and suggest that they can be used interchangeably.

Objective: To evaluate the association of surgical approach with overall survival after excision of localized T1/T2 MCC.

Design, setting, and participants: This retrospective cohort study used the National Cancer Database to assess adults with T1/T2 MCC who were diagnosed between January 1, 2004, and December 31, 2018, with pathologically confirmed, negative regional lymph nodes and treated with surgery. The National Cancer Database includes all reportable cases from Commission on Cancer-accredited facilities. Data analysis was performed from October 2022 to May 2023.

Exposure: Surgical approach.

Main outcomes and measures: Overall survival.

Results: A total of 2313 patients (mean [SD] age, 71 [10.6] years; 1340 [57.9%] male) were included in the study. Excision with MMS had the best unadjusted survival, with mean (SE) survival rates of 87.4% (3.4%) at 3 years, 84.5% (3.9%) at 5 years, and 81.8% (4.6%) at 10 years vs 86.1% (0.9%) at 3 years, 76.9% (1.2%) at 5 years, and 60.9% (2.0%) at 10 years for patients treated with WLE. Patients treated with narrow-margin excision had similar survival as those treated with WLE, with mean (SE) survival rates of 84.8% (1.4%) at 3 years, 78.3% (1.7%) at 5 years, and 60.8% (3.6%) at 10 years. On multivariable survival analysis, excision with MMS was associated with significantly improved survival compared with WLE (hazard ratio, 0.59; 95% CI, 0.36-0.97; P = .04). High-volume MCC centers were significantly more likely to use MMS over WLE compared with other centers (odds ratio, 1.99; 95% CI, 1.63-2.44; P < .001).

Conclusions and relevance: In this cohort study, the use of MMS (compared with WLE) was associated with significantly improved survival for patients with localized MCC with pathologically confirmed negative lymph nodes treated with surgery. These data suggest that Mohs surgery may provide a more effective treatment for MCC primary tumors than conventional WLE, although the lack of randomization and potential for selection bias in this study highlight the need for future prospective work evaluating this issue.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Carucci reported receiving grant funding from Regeneron for investigator-initiated basic research. No other disclosures were reported.

Figures

Figure.
Figure.. Kaplan-Meier Survival Curves Stratified According to Excision Modality
MMS indicates Mohs micrographic surgery; NME, narrow-margin excision; WLE, wide local excision.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Paulson KG, Park SY, Vandeven NA, et al. . Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457-463.e2. doi:10.1016/j.jaad.2017.10.028 - DOI - PMC - PubMed
    1. Fitzgerald TL, Dennis S, Kachare SD, Vohra NA, Wong JH, Zervos EE. Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surg. 2015;81(8):802-806. doi:10.1177/000313481508100819 - DOI - PubMed
    1. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49(5):832-841. doi:10.1016/S0190-9622(03)02108-X - DOI - PubMed
    1. Kieny A, Cribier B, Meyer N, Velten M, Jegu J, Lipsker D. Epidemiology of Merkel cell carcinoma: a population-based study from 1985 to 2013, in northeastern of France. Int J Cancer. 2019;144(4):741-745. doi:10.1002/ijc.31860 - DOI - PubMed
    1. Youlden DR, Soyer HP, Youl PH, Fritschi L, Baade PD. Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993-2010. JAMA Dermatol. 2014;150(8):864-872. doi:10.1001/jamadermatol.2014.124 - DOI - PubMed